Suppr超能文献

16S聚合酶链反应(PCR)联合桑格测序或新一代测序技术用于诊断脊柱骨髓炎的准确性如何?一项系统评价与Meta分析

What Is the Accuracy of 16S PCR Followed by Sanger Sequencing or Next-generation Sequencing in Native Vertebral Osteomyelitis? A Systematic Review and Meta-analysis.

作者信息

Mahmoud Omar K, Petri Francesco, El Zein Said, Fida Madiha, Diehn Felix E, Verdoorn Jared T, Schuetz Audrey N, Murad M Hassan, Nassr Ahmad, Berbari Elie F

机构信息

Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.

Department of Infectious Diseases, ASST Fatebenefratelli Sacco, "L. Sacco" University Hospital, Milan, Italy.

出版信息

Clin Orthop Relat Res. 2025 May 1;483(5):930-938. doi: 10.1097/CORR.0000000000003314. Epub 2024 Dec 5.

Abstract

BACKGROUND

Identifying a microorganism in patients with native vertebral osteomyelitis presents diagnostic challenges. Microorganism identification through culture-based methods is constrained by prolonged processing times and sensitivity limitations. Despite the availability of molecular diagnostic techniques for identifying microorganisms in native vertebral osteomyelitis, there is considerable variability in reported sensitivity and specificity across studies, leading to uncertainty in their clinical utility.

QUESTIONS/PURPOSES: What are the sensitivity, specificity, and diagnostic odds ratios for 16S broad-range PCR followed by Sanger sequencing (16S) and metagenomic next-generation sequencing (NGS) for detecting bacteria in native vertebral osteomyelitis?

METHODS

On June 29, 2023, we searched Cochrane, Embase, Medline, and Scopus for results from January 1970 to June 2023. Included studies involved adult patients with suspected native vertebral osteomyelitis undergoing molecular diagnostics-16S bacterial broad-range PCR followed by Sanger sequencing and shotgun or targeted metagenomic NGS-for bacteria detection. Studies involving nonnative vertebral osteomyelitis and cases of brucellar, tubercular, or fungal etiology were excluded. The reference standard for the diagnosis of native vertebral osteomyelitis was a composite clinical- and investigator-defined native vertebral osteomyelitis diagnosis. Diagnostic performance was assessed using a bivariate random-effects model. Risk of bias and diagnostic applicability were evaluated using the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. After a manual screening of 3403 studies, 10 studies (5 on 16S, 5 on NGS) were included in the present analysis, from which 391 patients were included from a total of 958 patients overall. Quality assessment via QUADAS-2 criteria showed moderate risk of bias and good applicability.

RESULTS

16S showed 78% (95% confidence interval [CI] 95% CI 31% to 96%) sensitivity and 94% (95% CI 73% to 99%) specificity, whereas NGS demonstrated 82% (95% CI 63% to 93%) sensitivity and 71% (95% CI 37% to 91%) specificity. In addition, the diagnostic ORs were 59 (95% CI 9 to 388) and 11 (95% CI 4 to 35) for 16S and NGS, respectively. Summary receiver operating characteristic curves showed high test performance for 16S (area under the curve for 16S 95% [95% CI 93% to 97%] and for NGS 89% [95% CI 86% to 92%]). Certainty in estimates was moderate because of sample size limitations.

CONCLUSION

This meta-analysis found moderate-to-high diagnostic performance of molecular methods on direct patient specimens for the diagnosis of native vertebral osteomyelitis. When used as a complementary test to microbiological analyses, a positive 16S result rules in the diagnosis of native vertebral osteomyelitis, while further studies are needed to understand the role of NGS in the diagnosis of native vertebral osteomyelitis. When available, these tests should be used in addition to conventional microbiology, especially in complex cases with extensively negative standard microbiological test results, to detect fastidious bacteria or to confirm the causative bacteria when their isolation and pathogenicity are unclear. A large sample size is needed in future research to understand the use of these techniques as standalone tests for diagnosis.

LEVEL OF EVIDENCE

Level III, diagnostic study.

摘要

背景

在原发性椎体骨髓炎患者中鉴定微生物存在诊断挑战。基于培养的微生物鉴定方法受处理时间长和灵敏度限制的约束。尽管有用于鉴定原发性椎体骨髓炎中微生物的分子诊断技术,但各研究报告的灵敏度和特异性存在很大差异,导致其临床实用性存在不确定性。

问题/目的:16S宽范围聚合酶链反应(PCR)联合桑格测序(16S)和宏基因组下一代测序(NGS)检测原发性椎体骨髓炎中细菌的灵敏度、特异性和诊断比值比是多少?

方法

2023年6月29日,我们检索了考克兰图书馆、Embase、Medline和Scopus数据库,获取1970年1月至2023年6月的研究结果。纳入的研究涉及疑似原发性椎体骨髓炎的成年患者,他们接受了分子诊断——16S细菌宽范围PCR联合桑格测序以及鸟枪法或靶向宏基因组NGS——用于细菌检测。排除涉及非原发性椎体骨髓炎以及布鲁氏菌、结核或真菌病因病例的研究。原发性椎体骨髓炎诊断的参考标准是综合临床和研究者定义的原发性椎体骨髓炎诊断。使用双变量随机效应模型评估诊断性能。使用修订后的诊断准确性研究质量评估(QUADAS - 2)工具评估偏倚风险和诊断适用性。在对3403项研究进行人工筛选后,本分析纳入了10项研究(5项关于16S,5项关于NGS),总共958例患者中纳入了391例。通过QUADAS - 2标准进行的质量评估显示偏倚风险为中度,适用性良好。

结果

16S的灵敏度为78%(95%置信区间[CI] 95% CI 31%至96%),特异性为94%(95% CI 73%至99%),而NGS的灵敏度为82%(95% CI 63%至93%),特异性为71%(95% CI 37%至91%)。此外,16S和NGS的诊断比值比分别为59(95% CI 9至388)和11(95% CI 4至35)。汇总的受试者工作特征曲线显示16S的检测性能较高(16S曲线下面积为95% [95% CI 93%至97%],NGS为89% [95% CI 86%至92%])。由于样本量限制,估计的确定性为中度。

结论

这项荟萃分析发现分子方法对直接患者标本诊断原发性椎体骨髓炎具有中到高的诊断性能。当用作微生物分析的补充检测时,16S阳性结果可确诊原发性椎体骨髓炎,而需要进一步研究以了解NGS在原发性椎体骨髓炎诊断中的作用。如有条件,这些检测应与传统微生物学检测一起使用,特别是在标准微生物学检测结果广泛为阴性的复杂病例中,以检测苛养菌或在细菌分离及致病性不明确时确认病原菌。未来研究需要大样本量以了解这些技术作为独立诊断检测的用途。

证据级别

III级,诊断性研究。

相似文献

5
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验